HCP Live covers significant developments in the field of gastroenterology during December 2023. Key highlights include:
American Gastroenterological Association (AGA) Guidelines: The AGA released two important guidelines in December. The first set of guidelines focuses on the use of biomarkers in managing Crohn’s Disease (CD), offering 11 conditional recommendations based on evidence and expert consensus. These guidelines emphasize the role of serum and fecal biomarkers as surrogates for endoscopic disease activity in CD. The second guideline pertains to the management of pouchitis and inflammatory pouch disorders, marking the first comprehensive evidence-based guideline in this area.
Qazi Corner’s Fourth Installment: This edition of HCPLive’s quarterly newsletter, Qazi Corner, featured insights from digestive disease experts at Cleveland Clinic. It highlighted new treatments and trials in gastroenterology, including a head-to-head trial data for therapies in CD, a new treatment for erosive esophagitis, an ulcerative colitis agent, and the latest American College of Gastroenterology (ACG) recommendations for Celiac disease.
Interviews and Insights: The article includes interviews with experts like Shubha Bhat, PharmD, who discusses etrasimod for ulcerative colitis, and Katie Falloon, MD, who talks about the SEQUENCE study comparing the efficacy and safety of ustekinumab and risankizumab in CD.
These developments reflect ongoing efforts to refine and improve gastroenterological care through evidence-based guidelines and innovative treatments.